论文部分内容阅读
目的:研究低分子量肝素治疗急性前循环脑梗死的有效性和安全性。方法:选择我院2000年6月～2001年6月收治的在发病48小时内就诊的急性前循环脑梗死患者,随机分为观察组(34例)和对照组(34例)。观察组患者使用低分子量肝素皮下注射(4 100u,每12小时1次,共10天)。于治疗前及治疗后10、21、28天评定临床神经功能缺损程度及疗效。结果:观察组治疗前后临床神经功能缺损评分比较具有极显著差异(P<0.01),与对照组比较有显著差异(P<0.05);第28天两组总有效率分别为76.5%和55.9%,两组比较有极显著差异(P<0.001)。结论:低分子量肝素治疗急性前循环脑梗死是安全有效的。
Objective: To study the efficacy and safety of low molecular weight heparin in the treatment of acute anterior circulation cerebral infarction. Methods: Acute anterior circulation cerebral infarction patients admitted to our hospital from June 2000 to June 2001 within 48 hours of onset were randomly divided into observation group (34 cases) and control group (34 cases). Patients in the observation group were injected subcutaneously with low molecular weight heparin (4 100u every 12 hours for 10 days). Before treatment and after treatment 10,21,28 days assessment of clinical neurological deficit and efficacy. Results: Compared with the control group, the score of clinical neurological deficit in the observation group had significant difference (P <0.01), and the total effective rate was 76.5% and 55.9% on the 28th day respectively There was significant difference between the two groups (P <0.001). Conclusion: Low molecular weight heparin is safe and effective in the treatment of acute anterior circulation cerebral infarction.